SHORT COMMUNICATION

Kidney cortical transporter expression across species using quantitative proteomics

Abdul Basit¹, Zaher Radi², Vishal S. Vaidya², Mathew Karasu¹, Bhagwat Prasad¹

¹ Department of Pharmaceutics, University of Washington, Seattle, P.O. Box 357610, WA 98195 USA

² Pfizer Worldwide Research Development, Drug Safety Research Development, One Portland Street, Cambridge, MA 02139 USA
Running Title: Quantitative profiling of kidney transporters across species

Corresponding author: Bhagwat Prasad, Ph.D., Department of Pharmaceutics, University of Washington, Seattle, P.O. Box 357610, WA 98195, USA. Phone: +1-206-221-2295. Fax: +1-206-543-3204. Email: bhagwat@uw.edu

Number of words –
Abstract: 205
Introduction: 414
Discussion: 1109

Abbreviations: ABB, ammonium bicarbonate buffer; BSA, bovine serum albumin; DTT, dithiothreitol; HSA, human serum albumin; IAA, iodoacetamide; LC-MS/MS, liquid chromatography-tandem mass spectrometry; PK, Pharmacokinetics; OAT, organic anion transporters; OATP, Organic anion transporter polypeptide; OCT, organic cation transporter; MATE1, Multidrug and toxin extrusion protein 1; MDR1, Multidrug resistance protein1; MRP, Multidrug resistance-associated protein; SGLT2, Sodium/glucose cotransporter 2; BCRP, Breast cancer resistance protein; OCTN1/2, Organic cation/carnitine transporter 1/2, SLC = Solute Carrier; SLCO = solute carrier organic anion transporter; ABCB = ATP-binding cassette sub-family B; ABCG = ATP-binding cassette super-family G; ABCC = ATP-binding cassette sub-family C
ABSTRACT

Limited understanding of species differences in kidney transporters is a critical knowledge gap for prediction of drug-induced acute kidney injury, drug interaction, and pharmacokinetics in humans. Here, we report protein abundance data of nineteen transporters in the kidney cortex across five species (human, monkey, dog, rat, and mouse). In general, the abundance of all the 19 membrane transporters was higher in preclinical species as compared to human except for MDR1, OCT3 and OCTN1. In nonhuman primate, the total abundance of 12 transporters for which absolute data were available, was 2.1-fold higher (p value = 0.025) relative to human but the % distribution of these transporters was identical in both species. MRP4, OCTN2, OAT2, Na⁺K⁺ATPase, MRP3, SGLT2, OAT1, MRP1, MDR1, OCT2 were expressed differently with cross-species variability of 8.2, 7.4, 6.1, 5.9, 5.4, 5.2, 4.1, 3.3 and 2.8-fold, respectively. Sex differences were only significant in rodents and dog. High protein-protein correlation was observed in OAT1 versus MRP2/MRP4 as well as OCT2 versus MATE1 in human and monkey. The cross-species and sex-dependent protein abundance data are important for animal to human scaling of drug clearance as well as for mechanistic understanding of kidney physiology and derisking of kidney toxicity for new therapeutic candidates in drug development.
INTRODUCTION

In the early toxicity assessment of candidate therapeutics in drug development, the data obtained from animal models need to be interpreted with caution for predicting human pharmacokinetics (PK) (Tang and Mayersohn, 2011), risk of organ injury as well as drug-drug interaction (DDI) (Fisel et al., 2014). Clinical and preclinical species differences in the mRNA expression, protein abundance and activity of transporters in organs relevant to drug disposition (i.e., intestine, liver, and kidney) remain a major reason for the poor allometric scaling (Wang et al., 2015). Although significant progress has been made towards the understanding of species and sex differences of drug transporters in the liver (Wang et al., 2015), limited data exist in the kidney and intestine. Particularly, kidney transporters can affect systemic drug clearance by regulating drug secretion and/or reabsorption and contribute to kidney toxicity by affecting intracellular drug concentration (Filipski et al., 2009). For example, kidney toxicity of tenofovir, methotrexate, cisplatin, ifosfamide, ciprofloxacin, and sitagliptin is associated with solute carrier (SLC) transporters such as organic anion transporters (OATs) or organic cation transporters (OCTs) (Fisel et al., 2014) (Figure 1). Allometric scaling methods are used for extrapolation of preclinical renal disposition data to human (Zou et al., 2012), however these methods are not always successful particularly when a drug undergoes kidney transport and metabolism. For example, tenofovir is taken up into proximal tubules mainly by OAT1 and effluxed into the urine by MRP4, and both of these transporters are shown to be associated with tenofovir kidney toxicity (Kohler et al., 2011). Further, examples exist where kidney toxicity is different in male and female, e.g., cisplatin, an OCT2 substrate, is more toxic to male rats (Nematbakhsh et al., 2013). In addition, rises in serum creatinine (sCr) is used as a surrogate of kidney function. However, as a fraction of sCr is secreted by active transporters, cross-species and sex-dependent variability in the sCr transport could lead
to false positive or negative conclusions regarding the kidney function. Particularly, rise in sCr could be a result of inhibition of renal transporters without direct kidney injury (Chu et al., 2016).

Therefore, characterization of the cross-species and sex-dependent differences in protein abundances of kidney transporters is important for scaling and better prediction of renal secretion, reabsorption, and toxicity in humans. Accordingly, we hypothesized that mapping interspecies and sex-differences in the abundance of kidney cortical transporters would enable development of physiologically-based PK (PBPK) models that will improve the prediction of PK, kidney toxicity, and the potential risk of DDIs.

MATERIALS AND METHODS

Chemicals and reagents

LC-MS grade acetonitrile, methanol, chloroform and formic acid were purchased from Fisher scientific (Fair Lawn, NJ, USA) and formic acid was purchased from Sigma-Aldrich (St. Louis, MO). The ProteoExtract native membrane protein extraction kit was procured from Pierce Biotechnology (Rockford, IL). The protein quantification BCA kit and the in-solution trypsin digestion kit were purchased from Pierce Biotechnology (Rockford, IL). Iodoacetamide (IAA), dithiothreitol (DTT), and pierce trypsin protease (MS grade) were purchased from Thermo Fisher Scientific (Rockford, IL). Ammonium bicarbonate buffer (ABC, 98% purity) was purchased from Acros Organics (Geel, Belgium). Human serum albumin (HSA) and bovine serum albumin (BSA) were obtained from Calbiochem (Billerica, MA) and Thermo Fisher Scientific (Rockford, IL), respectively. Surrogate light and heavy peptides were obtained from New England Peptides (Boston, MA) and Thermo Fisher Scientific (Rockford, IL), respectively. OAT1 antibody was procured from Abcam (Cambridge, MA), anti-mouse IgG, HRP-linked secondary antibody was
purchased from (Cell signaling technologies) and SDS gel (Mini-PROTEAN TGX) was from BIO-RAD (Hercules, CA).

Procurement of normal kidney cortices from experimental animals

Normal kidney cortical tissue (approximately 100-150 mg) was collected consistently at autopsy from the same kidney region from the preclinical species, i.e., Cynomolgus monkey (n = 11; 5 male and 6 female), Beagle dog (n = 12; 6 male and 6 female), Wistar Han rat (n = 20; 10 male and 10 female), and CD-1 mouse (n = 18; 8 male and 10 female). The autopsies were conducted at the Pfizer Worldwide R&D facility (Cambridge, MA), which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. After collection, kidney tissue was flash frozen and stored at -80 °C before shipping to the University of Washington. The study was conducted in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals and in compliance with the Animal Welfare Act and its implementing regulations, under Institutional Animal Care and Use Committee approved protocols.

Membrane protein isolation from kidney tissue

Total membrane protein was extracted from the kidney cortex (~30-60 mg) of preclinical species using a previously described protocol (Xu et al., 2018). In brief, 30-60 mg of kidney cortical tissue were homogenized using hand-held rotary homogenizer with plastic probes. The homogenate was centrifuged at 16000 x g for 30 min at 4°C. The supernatant (cytosolic fraction) was transferred to a new tube and the remaining pellet (membrane fraction) was resuspended with 600 µL of solubilization buffer (Pierce Biotechnology, Rockford, IL) and incubated at 4°C for 30 min with continuous mixing. Membrane fraction was used for the transporters quantification.
Peptide selection and LC-MS/MS protein quantification of kidney drug transporters

We applied an optimized LC-MS/MS methodology, which relies on selective quantification of surrogate peptides of drug transporters. Whenever applicable, conserved peptides across species were selected for precise comparison. When conserved peptides were not available, a novel matrix approach (supplemental Figure 1) was used.

Peptide selection for individual drug transporters (Supplemental Table 1) in kidney across species was performed using a previously discussed in silico approach (Bhatt and Prasad, 2018). Total protein in kidney samples was quantified using a bicinchoninic acid (BCA) assay kit (Pierce Biotechnology, Rockford, IL) following the vendor protocol. Samples were digested as described previously (Bhatt et al., 2018). Briefly, 80 µL of the membrane sample (2 mg/mL total protein) was mixed with 30 µL ABC (100 mM), 10 µL of HSA (10 mg/mL) and 20 µL of BSA (0.02 mg/ml) in 1.5 mL micro-centrifuge tube. Proteins were denatured and reduced with 10 µL of 250 mM DTT at 95°C for 10 min with gentle shaking at 300 rpm. Sample was cooled at room temperature for 10 min, and the denatured protein was alkylated with 20 µL of 500 mM IAA; the reaction was carried out in the dark for 30 min. Ice-cold methanol-chloroform (600 µL, 5:1 v/v) and water (400 µL) were subsequently added to each sample. After vortex-mixing and centrifugation at 16,000 × g (4°C) for 5 min, the upper aqueous and lower organic layers were carefully removed without disturbing the protein pellet, using vacuum suction. The protein pellet was dried at room temperature for 10 min and then washed with 500 µL ice-cold methanol and followed centrifugation at 8000 × g (4°C) for 5 min. Supernatant was removed, pellet was dried at room temperature for 30 min and re-suspended in 60 µL ABC buffer (50 mM, pH 7.8). Finally,
reconstituted protein sample was digested by adding 20 μL of trypsin (protein: trypsin ratio, approximately 50:1) and incubated at 37°C for 16 hours. The reaction was quenched by the addition of 20 μL of peptide internal standard cocktail (prepared in 80% acetonitrile in water containing 0.5% formic acid) and 10 μL 80% acetonitrile in water containing 0.5% formic acid. The sample was mixed by vortex mixing, and centrifuged at 4000 ×g for 5 min. The supernatant was collected in a LC-MS vial for analysis. LC-MS/MS data acquisition was performed on Waters Acquity UPLC system coupled with a SCIEX API-6500 triple quadrupole mass spectrometer using optimized parameters outlined in Supplemental Tables 2 and 3 as per validated method described previously (Prasad et al., 2016). LC-MS/MS data analysis is discussed in the supplementary file. Previously published human transporter levels were used as reference data (Prasad et al., 2016), whereas an archived pooled (n=21) human kidney tissue sample from our previous study was analyzed along with the animal samples as a quality control.

To control for cross-species variability in the membrane isolation recovery, we have utilized total membrane protein per gram of kidney (TM-PPGK), which served as a scaling factor to express data in pmol/gram unit. This scaling was particularly important as TM-PPGK value for human (Supplemental Figure 2) was significantly lower among species.

To validate results of LC-MS/MS, Western blotting analysis of a representative protein, OAT1 was performed using established protocol (Neradugomma et al., 2017) (Supplementary file).

**RESULTS**

**Cross-species kidney cortical transporter abundances**

We quantified and investigated nineteen basolateral and apical membrane transporters in normal kidneys cortex obtained from four commonly used preclinical species in toxicity studies and drug
safety evaluation and development, i.e., nonhuman primates (Cynomolgus monkeys), Beagle dogs, Wistar Han rats, and CD1 mice. These data were compared with our previously generated human kidney data (Prasad et al., 2016). We report absolute data for 12 transporters (pmol/gram of tissue) and relative abundance (normalized to total protein) data for seven transporters (Figure 2 and Supplemental Table 4). In general, the abundance of all the 19 membrane transporters were higher in preclinical species as compared to human except for MDR1, OCT3 and OCTN1 (Figure 2B). Human MDR1 abundance is similar to monkey, dog and rat, but it was higher (2.5 fold; p value <0.05) than mouse MDR1. OCT3 is only detectable in human and OCTN1 was similar in human and monkey. In nonhuman primate, the total abundance of 12 transporters for which absolute data were available, was 2.1-fold higher (p = 0.025) relative to human but the % distribution of these transporters was identical in both the species (Supplemental Figure 3). The abundances of OAT1, OCTN2, SGLT2, MRP1, Na⁺K⁺ATPase, and MRP3 were highest in rat and lowest in human with fold-range of 2.9 to 7.4 (p value <0.05). MRP4 was highest in nonhuman primate and lowest in mouse. The abundance of OAT2 was ~ 5-fold (p value <0.0001) higher in mouse as compared to human and nonhuman primate and it was undetectable in rat. MATE1, MRP2, OAT3, OAT4 and OATP4C1 were 1.5-2.3-fold (p value <0.05) higher in nonhuman primate than human. OCT1 and BCRP were only detected in rodents. SGLT2 and Na⁺K⁺ATPase were 2- to 6- fold higher in all four preclinical species than human (p value <0.05). A significant correlation was observed between transporters (Figure 2C).

Sex differences in kidney cortical transporter abundances

Transporter abundance in human and nonhuman primate kidney did not show sex-dependent pattern. Significant sex differences in transporter abundance were observed in mouse followed by rat > dog (Table 1). OAT1 was higher by 3.2 and 1.3-fold (p value <0.05) in male mouse and rat,
respectively. OAT2 was 1.6-fold higher in male mouse than the female. OCT2 was higher in male rat and mouse. MDR1 was 2- and 1.4-fold higher (p value <0.05) in female in mouse and dog, respectively. Whereas MDR1 abundance was higher in male rat by 1.6-fold. MRP4 is predominantly expressed in male mouse (2.4-fold, p value <0.05) kidney. OCTN2 abundance was 1.3 and 1.4 fold higher in female mouse and male rats, respectively. SGLT2 was only 1.2 fold higher (p value <0.05) in female rats.

Comparison of LC-MS/MS proteomics and Western blot data of a representative transporter, OAT1

Antibodies are not available for all the studied transporters and when available, these do not work for all the species. Nevertheless, we performed OAT1 quantification by Western blotting using an anti-mouse OAT1 antibody to validate the LC-MS/MS data (method discussed in supplementary information). The sex-difference in OAT1 abundance in mouse is qualitatively confirmed by the Western blot data (Supplemental Figure 4). The higher signal of OAT1 in rat sample was consistent with the proteomics data; however, the antibody did not work for human OAT1 (data not shown).

DISCUSSION

Here we report comparison of nineteen clinically relevant kidney drug transporters between human and four common preclinical animal models used in drug development. The presented data are the total membrane expression because it is technically difficult to reproducibly extract purified plasma membrane from frozen tissues (Kumar et al., 2015). While the plasma membrane isolation involves multiple steps, we have previously demonstrated that the total membrane extraction from
different parts of kidney is highly reproducible using the total membrane extraction kit (Prasad et al., 2016).

The quantitative information on cross species transporter abundance is useful in interpreting kidney safety data in humans. Particularly, drug-induced modest (20-30%) rises in sCr in preclinical models could be due to direct tubular damage (i.e., drug-induced kidney injury [DIKI]) or indirect inhibition of kidney transporters. For example, an investigational Janus Kinase inhibitor, INCB039110, resulted in rises in sCr in a healthy volunteer's study (Zhang et al., 2015). A follow-up dedicated kidney investigative clinical study revealed no changes in FDA/EMA qualified nonclinical kidney toxicity biomarkers (e.g., Cystatin C) or glomerular filtration rate (GFR), but rather the rises in sCr were attributed to interference with kidney uptake transporters such as OCT2, OCT3 and OAT2 (Zhang et al., 2015) and efflux transporters such as MATE1 and MATE2K (Lepist et al., 2014; Zhang et al., 2015). Thus, understanding which transporters are potentially involved in uptake or efflux of the therapeutic candidate and knowing the relative abundance of the transporter across nonclinical species and humans will allow better interpretation of clinical data.

This dataset for species and sex specific abundances for kidney transporters is also useful to the biomedical community and drug developers in predicting the drug clearance and safety of new molecule entities. In agreement with our data, OCT1 and BCRP are not detected in human and nonhuman primate but were abundant in rodents (Bleasby et al., 2006; Prasad et al., 2016). The relatively low abundance of MDR1 in mouse kidney as compared to human and rat is consistent with the mRNA data (Bleasby et al., 2006). Similarly, both nonhuman primate and rat have been shown to be associated with kidney toxicity with repeated dosing of tenofovir but such toxicity was not observed in the mouse at a similar dose (Ng et al., 2015; Ustianowski and Arends, 2015).
High correlation between OAT1 versus MRP2 and MRP4 indicates that the latter are important for the apical efflux of organic anions. Similarly, high correlation of cation transporters, OCT2 and MATE1 in human and nonhuman primate perhaps suggests that these transporters are co-regulated. We also observed that OAT2 (a sCr secreting transporter) is a highly abundant anion transporter in mouse, whereas, OAT1 is predominantly expressed in other species. Therefore, results of individual OAT knockout mouse versus rat are expected to be significantly different.

Differential sex abundance in mouse and rats (Table 1) was supported by negative correlations between transporters (Figure 3). Particularly, in mouse, the basolateral uptake transporters such as OATs and OCT2 were higher in male but the apical transporters (primarily efflux) were higher in females. In rats, sex-dependent regulation of the basolateral uptake transporters was consistent with mouse, however, OCTN2, BCRP and P-gp were also higher in males. Although, mechanisms of sex-dependent expression of these proteins is unknown, these transporters are important in secretion of conjugated sex-hormones (Bush et al., 2017) and therefore can be regulated by the latter. Consistent with our data, abundance or activity of some OATs and OCTs have been shown to be sex-dependent (Cerrutti et al., 2002; Groves et al., 2006; Breljak et al., 2010; da Silva Faria et al., 2015).

Good correlation of OAT1 and OAT3 abundances is supported by the fact that these are transcriptionally co-regulated (Prasad et al., 2016). Because most of the co-regulated proteins work in tandem (OCT vs. MATE and OAT vs. MRPs) in vectorial transport process, a substrate mediated regulation could be tested as potential mechanisms of correlations.

Regarding limitations of this study, it does not allow comparison of all transporters because of the lack of MS-quantifiable or conserved peptides across species (e.g., dog). Nevertheless, our novel
LC-MS/MS proteomics method allowed quantification of a majority of kidney transporters across species, which is not currently feasible using conventional immunoquantification. We also demonstrated that the quality of LC-MS/MS proteomics data is superior to Western blot data using OAT1 as an example (Supplementary Figure 4). In addition, the protein abundance data (in the absence of in vitro functional data) are limited for the prediction of species differences in drug induced kidney injury or PK. However, the transporter abundance data are critical piece of information (i.e., a prerequisite), which constitute key physiological parameters for PBPK modeling (Harwood et al., 2013). Particularly, these data can be integrated with transport kinetics data (e.g., Km, Equation 1) of a drug or new chemical entity to predict in vivo transporter activity in animal models versus human (Equation 2). Further, sex-dependent quantitative differences in the transporter abundance can be directly integrated into a PBPK model to extrapolate drug PK or drug toxicity (Equations 1 and 3); where Km can be assumed similar between male versus female in a single species.

\[ CL = \frac{V_{\text{max}}}{K_m + [S]} = \frac{[\text{Abundance} \times K_{\text{cat}}]}{K_m + [S]} \]  

(Equation 1)

Thus,

\[ CL_{\text{human}} \propto CL_{\text{animal}} \times \frac{[\text{Abundance}_{\text{human}}]}{[\text{Abundance}_{\text{animal}}]} \]  

(Equation 2)

\[ CL_{\text{female}} = CL_{\text{male}} \times \frac{[\text{Abundance}_{\text{human}}]}{[\text{Abundance}_{\text{animal}}]} \]  

(Equation 3)

Where, CL is intrinsic clearance (pmol/min/mg protein or pmol/min/gm of kidney), \( V_{\text{max}} \) is the maximum transport activity, \( K_m \) is substrate affinity to a transporter, \( K_{\text{cat}} \) is the turnover number
and \([S]\) is the substrate concentration. \(V_{\text{max}}\) depends on the transporter abundance, whereas \(K_m\) and \(K_{\text{cat}}\) are independent of protein levels (Bhatt and Prasad, 2018). It is also noteworthy that the data obtained from the absolute peptide approach should not be considered as absolute molar protein abundance data because complete trypsin digestion may not be confirmed. However, these data (absolute peptide levels) can be used in allometric scaling of animal to human transporter mediated clearances using Equations 1-3. Because the scaling factor is derived by dividing the peptide abundance values, it does not matter whether absolute protein or absolute peptide values were used in the scaling as long as the trypsin digestion and the sample extraction are reproducible and consistent across species/genders. We have previously described this scaling approach (Bhatt and Prasad, 2018).

In summary, our data on cross-species kidney transporter abundances, particularly in human, monkey and rodents, provide useful quantitative information, which can be leveraged by: 1) allowing for preclinical to clinical translation of transporter mediated secretary clearance using PBPK modeling, 2) distinguishing direct drug-induced kidney toxicity from indirect impact on kidney transporters (e.g., transporter mediated creatinine clearance), and 3) utilizing cross-species transporter levels in conjunction with kidney injury biomarkers to better understand kidney safety signals and human safety risk assessment.

**Acknowledgement:** This project was supported and funded by Pfizer Inc. Authors would like to thank Dr. Naveen Neradugomma for his help in the Western blotting analysis.
Author contribution

Participated in research design: A.B., Z.R., V.S.V., and B.P.

Conducted experiments: A.B. and M.K.

Performed data analysis: A.B. and B.P.

Wrote or contributed to the writing of the manuscript: A.B., Z.R., V.S.V., and B.P.
References


spectrometry: addressing methodologic issues of plasma membrane isolation and

Huang Y, and Ray AS (2014) Contribution of the organic anion transporter OAT2 to the
renal active tubular secretion of creatinine and mechanism for serum creatinine elevations

Gender difference in Cisplatin-induced nephrotoxicity in a rat model: greater intensity of
damage in male than female. *Nephrourol Mon* **5**:818-821.

Neradugomma NK, Liao MZ, and Mao Q (2017) Buprenorphine, Norbuprenorphine, R-
Methadone, and S-Methadone Upregulate BCRP/ABCG2 Expression by Activating Aryl

disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks
of oral administration in mice. *Int J Toxicol* **34**:4-10.

Prasad B, Johnson K, Billington S, Lee C, Chung GW, Brown CD, Kelly EJ, Himmelfarb J, and
Unadkat JD (2016) Abundance of Drug Transporters in the Human Kidney Cortex as

clearance: an historical problem and reflections on what works and what does not. *Curr

Ustianowski A and Arends JE (2015) Tenofovir: What We Have Learnt After 7.5 Million


Footnotes

Zaher Radi and Vishal Vaidya are employed by Pfizer Inc.
Figure legends

Figure 1: Localization of drug transporters in proximal tubule. Kidney proximal tubule contains OAT1-3, OATP4C1, OCT1-3, and MRP1/3 at the basolateral membrane and MATE1, MATE2k, MDR1, MRP2/4, SGLT2, OAT4, and OCTN1/2 at the apical membrane. Both uptake and efflux drug transporters are involved in nephrotoxicity of certain drugs shown in the figure.

Figure 2: A. Kidney cortical transporters cross-species comparison of protein abundance (pmol/gram tissue) expression. Each dot represents the individual sample and data are represented as mean ± SD. MATE-2K was not detectable in any species because of poor sensitivity of the surrogate peptide. Only six transporters were detected in dog kidney because of the lack of conserved peptides. B. Heat map of relative quantitative abundance of kidney transporters across species. Value in the cell represents the relative abundance of transporters across different species as compared to transporter abundance in human kidney. Yellow to red color indicates increasing abundance of a particular transporter across species.

Figure 3: A. Correlation plot for kidney transporter proteins across all five species. Values in the cell represents the coefficient of correlation ($r^2$) between two transporter proteins. B. Positive correlation between the transporter proteins with $r^2 > 0.70$. Number of samples from individual species used in this study (with few exceptions) was: human (n=34), monkey (n=11), dog (n=12), rat (n=20), and mouse (n=18). NC (not conserved) indicates that a conserved peptide was not found for that particular species. BLQ means below limit of quantification but the peptide was conserved. BLQ values were derived by extrapolation of signal-to-noise ratio to 3. NS indicates that no significant correlation ($r^2 < 0.70$) was found between transporter proteins.
Table 1: Sex differences in protein abundance of transporters across species.

<table>
<thead>
<tr>
<th>Proteins</th>
<th>Human</th>
<th>Monkey</th>
<th>Dog</th>
<th>Rat</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLC22A6 / Organic anion transporter 1 (OAT1)</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>M &gt; F *1.3</td>
<td>M &gt; F *3.2</td>
</tr>
<tr>
<td>SLC22A7 / Organic anion transporter 2 (OAT2)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>BLQ</td>
<td>M &gt; F *1.6</td>
</tr>
<tr>
<td>SLC22A8 / Organic anion transporter 3 (OAT3)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>SLC22A11 / Organic anion transporter 4 (OAT4)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>SLCO4C1 / Organic anion transporter polypeptide 4C1 (OATP4C1)</td>
<td>ND</td>
<td>↔</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>SLC22A1 / Organic cation transporter 1 (OCT1)</td>
<td>BLQ</td>
<td>BLQ</td>
<td>NC</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>SLC22A2 / Organic cation transporter 2 (OCT2)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>M &gt; F *1.4</td>
<td>M &gt; F *1.6</td>
</tr>
<tr>
<td>SLC22A4 / Organic cation/carnitine transporter 1 (OCTN1)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>SLC22A5 / Organic cation/carnitine transporter 2 (OCTN2)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>M &gt; F *1.4</td>
<td>F &gt; M *1.3</td>
</tr>
<tr>
<td>ABCB1 / Multidrug resistance protein 1 (MDR1)</td>
<td>↔</td>
<td>↔</td>
<td>F &gt; M *1.4</td>
<td>M &gt; F *1.6</td>
<td>F &gt; M *2.0</td>
</tr>
<tr>
<td>SLC47A1 / Multidrug and toxin extrusion protein 1 (MATE1)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>ABCG2 / Breast cancer resistance protein (BCRP)</td>
<td>BLQ</td>
<td>BLQ</td>
<td>NC</td>
<td>M &gt; F *1.6</td>
<td>↔</td>
</tr>
<tr>
<td>ABCC1 / Multidrug resistance-associated protein 1 (MRP1)</td>
<td>ND</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>F &gt; M *1.3</td>
</tr>
<tr>
<td>ABCC2 / Multidrug resistance-associated protein 2 (MRP2)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>ABCC3 / Multidrug resistance-associated protein 3 (MRP3)</td>
<td>ND</td>
<td>↔</td>
<td>NC</td>
<td>F &gt; M *1.1</td>
<td>F &gt; M *3.1</td>
</tr>
<tr>
<td>ABCC4 / Multidrug resistance-associated protein 4 (MRP4)</td>
<td>↔</td>
<td>↔</td>
<td>NC</td>
<td>↔</td>
<td>F &gt; M *2.4</td>
</tr>
<tr>
<td>SLC5A2 / Sodium/glucose cotransporter 2 (SGLT2)</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>F &gt; M *1.2</td>
<td>↔</td>
</tr>
<tr>
<td>ATP1A1 / Sodium/potassium-transporting ATPase (Na+K+ATPase)</td>
<td>ND</td>
<td>↔</td>
<td>F &gt; M *1.3</td>
<td>↔</td>
<td>↔</td>
</tr>
</tbody>
</table>

SLC = Solute Carrier; SLCO = solute carrier organic anion transporter; ABCB = ATP-binding cassette sub-family B; ABCG = ATP-binding cassette super-family G; ABCC = ATP-binding cassette sub-family C; ↔=No significant difference, NC=Peptide not conserved, *=Fold difference, BLQ= Below limit of quantification, ND = sex difference was not determined, data was obtained with pooled QC
Figure 1

![Diagram showing the transport of drugs through the kidney.]

**Blood**
- Tenofovir, Cidofovir, Adefovir
- Cephaloridin, Methotrexate, Acyclovir, Mercury
- Ciprofloxacin, Sitagliptin, acyclovir
- Cisplatin, Ifosfamide, Nitidine chloride

**Proximal tubule**
- OAT1
- OAT2
- OAT3
- OCT1
- OCT2
- OCT3
- OATP4C1
- MRP1
- MRP3

**Kidney Toxicity**

**Urine**
- MATE1
- MATE2K
- MDR1
- MRP2
- MRP4
- SGLT2
- OAT4
- OCTN1
- OCTN2

**Basolateral membrane**

**Apical (luminal) membrane**

Nitidine chloride
Cisplatin
Tenofovir?
Figure 3:

A

Mouse

Rat

Dog

Human

 Monkey

B

| Transporters (Proteins) | OAT1 | OAT3 | OAT4 | OAT2 | OCT1 | OCT2 | OCT3 | OCTN1 | OCTN3 | MATE1 | MATE2 | MRP1 | MRP2 | MRP3 | MRP4 | SIG15 | No of ATRs
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>SIG15</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Monkey</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>MRP4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>SIG15</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
</tbody>
</table>

Legend:
- 1: Present
- 0: Absent
- X: No data available